Product
Amifostine
Aliases
amifostine trihydrate
Name
Ethyol
INN Name
amifostine
FDA Approved
Yes
5 clinical trials
1 organization
8 indications
1 document
Indication
lung cancerIndication
Drug/Agent Toxicity by Tissue/OrganIndication
Multiple MyelomaIndication
Breast CancerIndication
LeukemiaIndication
Myelodysplastic SyndromesIndication
NeutropeniaIndication
Colorectal CancerClinical trial
A Phase I Study of Cytoreductive Surgery and Hyperthermic Intrathoracic Pleural Chemotherapy (HITC) With Escalating Doses for Children and Adolescents With Unilateral Pleural MalignancyStatus: Completed, Estimated PCD: 2020-08-25
Clinical trial
A Phase I Study of Amifostine Followed by High-Dose Escalation of Melphalan With Stem Cell Reconstitution for Patients With Primary Systemic AmyloidosisStatus: Terminated, Estimated PCD: 2007-09-01
Clinical trial
High-Dose Infusional Taxol, Amifostine, Doxorubicin, and Cyclophosphamide Followed by Stem Cell Rescue for High Risk Primary and Responsive Metastatic Breast CancerStatus: Completed, Estimated PCD: 2023-03-21
Clinical trial
Treatment of Poor Prognosis Acute Myeloid Leukemia and Blastic Crisis Chronic Myelogenous Leukemia With Mylotarg, High-Dose Cytarabine, Mitozantrone and Ethyol AML/CML 2000-06.Status: Withdrawn, Estimated PCD: 2004-04-07
Clinical trial
Phase II Study of the Efficacy of Amifostine (Ethyol) in Reducing the Incidence and Severity of Oxaliplatin-Induced Neuropathy in Patients With Colorectal CancerStatus: Terminated, Estimated PCD: 2010-01-13
Document
DailyMed Label: EthyolOrganization
Clinigen Limited